Specifically, the Company believes the non-GAAP measures provide useful information to both management and investors by isolating certain expenses, gains and losses that may not be indicative of its core operating results and business outlook. In addition, the Company believes non-GAAP measures that exclude stock-based compensation expense enhance the comparability of results against prior periods. The non-GAAP measures and the reconciliation to the most directly comparable GAAP measure of all non-GAAP measures are as follows:
Three Months Ended Six Months Ended
December 31, December 31,
2008 2007 2008 2007
Net Loss $(696,995) $(639,346) $(1,177,857) $(1,468,137)
Non-GAAP
adjustments:
Stock based
compensation $ 37,444 $ 159,977 $ 186,312 $ 172,911
Depreciation and
amortization $ 165,316 $ 151,245 $ 332,414 $ 296,328
Total adjustments $ 202,760 $ 311,222 $ 518,726 $ 469,239
Non-GAAP
adjusted loss $(494,235) $(328,124) $ (659,131) $ (998,898)
Shares used
in computing
basic and
fully diluted
earnings per
share 6,858,374 6,389,315 6,636,152 6,388,701
Non-GAAP
adjusted
loss per
fully diluted
share $ (0.08) $ (0.05) $ (0.10) $ (0.16)
Founded in 1987, the Company (http://www.escalonmed.com) develops markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products as well as vascular access devices. Drew Scientific, which operates as a separate business unit, provides instrumentation and consumables for
'/>"/>
| SOURCE Escalon Medical Corp. Copyright©2009 PR Newswire. All rights reserved |